Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press2110.17650/1726-9776-2014-10-1-58-63PROSTATE CANCERРАК ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫQUALITY OF LIFE IN PATIENTS OVER 70 YEARS OLD AFTER RADICAL SURGERY FOR PROSTATE CANCERКАЧЕСТВО ЖИЗНИ ПАЦИЕНТОВ СТАРШЕ 70 ЛЕТ, ПЕРЕНЕСШИХ РАДИКАЛЬНОЕ ОПЕРАТИВНОЕ ЛЕЧЕНИЕ ПО ПОВОДУ РАКА ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫBormotinA. V.БормотинА. В.
Russian Federation

Кафедра урологии

bormotin@nm.ruRevaI. A.РеваИ. А.
Russian Federation

Кафедра урологии

bormotin@nm.ruDyakovV. V.ДьяковВ. В.
Russian Federation

Кафедра урологии

bormotin@nm.ruBernikovA. N.БерниковА. Н.
Russian Federation

Кафедра урологии

bormotin@nm.ruPushkarD. Yu.ПушкарьД. Ю.
Russian Federation

Кафедра урологии

bormotin@nm.ruDepartment of Urology, A.I. Evdokimov Moscow State University of Medicine and DentistryМГМСУ им. А. И. Евдокимова3003201410158632407201424072014https://oncourology.abvpress.ru/oncur/article/view/21

Prostate cancer (PC) is the most common cancer among elderly males in the countries of North America and Europe. The mean age of patients with PC is 72–74 years old. A decision on a treatment option for elderly patients must be based on their somatic status and desire. Today radical operations for locally advanced PC are most commonly performed in older age groups (over 70 years). This is associated with the improvement of both medical equipment and surgical techniques. The patients’ good surgery tolerability is combined with satisfactory oncological results. However, because of age, the regenerative capacities of the patients in this group are diminished and postoperative restorative processes are slower and more difficult. Quality of life was assessed in the patients aged over 70 years who had undergone radical surgery in  our clinic for PC in the past 2 years.

 

Рак предстательной железы (РПЖ) является наиболее часто встречаемым злокачественным заболеванием среди пожилых мужчин в странах Северной Америки и Европы. Средний возраст больных РПЖ составляет 72–74 года. В отношении пожилых пациентов принятие решения о выборе метода лечения должно строиться на основании оценки риска прогрессирования заболевания с учетом соматического статуса и желания больного. В наши дни радикальное оперативное лечение локализованного РПЖ все чаще проводится пациентам старшей возрастной категории (старше 70 лет). Это связано как с совершенствованием медицинского оборудования, так и с улучшением оперативной техники. Хорошая переносимость пациентами операции сочетается с удов-летворительным онкологическим результатом. Однако ввиду возраста регенеративные возможности организма пациентов этой группы снижены, процессы восстановления в послеоперационном периоде протекают медленнее и труднее. Мы провели оценку качества жизни пациентов старше 70 лет, перенесших в нашей клинике радикальное оперативное лечение по поводу РПЖ за последние 2 года.

 

prostate cancerolder age group patientsradical prostatectomyquality of lifeрак предстательной железыпациенты старшей возрастной группырадикальная простатэктомиякачество жизни1. Grцnberg H. Prostate cancer epidemiology. Lancet. 2003;361:859–864.Grцnberg H. Prostate cancer epidemiology. Lancet. 2003;361:859–864.2. Hsing A. W., Chokkalingam A. P. Prostate cancer epidemiology. Front Biosci 2006;11:1388–413.Hsing A. W., Chokkalingam A. P. Prostate cancer epidemiology. Front Biosci 2006;11:1388–413.3. Ries L. A.G., Melbert D., Krapcho M. et al. SEER Cancer Statistics Review. 1975–2004. National Cancer Institute, Bethesda, MD, 2007.Ries L. A.G., Melbert D., Krapcho M. et al. SEER Cancer Statistics Review. 1975–2004. National Cancer Institute, Bethesda, MD, 2007.4. Crawford E. D. Epidemiology of prostate cancer. Urology 2003;62 (6 suppl 1):3–12.Crawford E. D. Epidemiology of prostate cancer. Urology 2003;62 (6 suppl 1):3–12.5. Jemal A., Siegel R., Ward E. et al. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43–66. 6. Sanda M. G., Dunn R. L., Michalski J. et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008;358:1250–61.Jemal A., Siegel R., Ward E. et al. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43–66. 6. Sanda M. G., Dunn R. L., Michalski J. et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008;358:1250–61.7. Albertsen P. C., Hanley J. A., Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005;293:2095–101.Albertsen P. C., Hanley J. A., Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005;293:2095–101.8. D’Amico A. V., Moul J., Carroll P. R. et al. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostatespecific antigen era. J Clin Oncol 2003;21:2163–72.D’Amico A. V., Moul J., Carroll P. R. et al. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostatespecific antigen era. J Clin Oncol 2003;21:2163–72.9. Chen A. B., D’Amico A. V., Neville B. A. et al. Patient and treatment factors associated with complications after prostate brachy therapy. J Clin Oncol 2006; 24:5298–304.Chen A. B., D’Amico A. V., Neville B. A. et al. Patient and treatment factors associated with complications after prostate brachy therapy. J Clin Oncol 2006; 24:5298–304.10. Saigal C. S., Gore J. L., Krupski T. L. et al. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 2007;110: 1493–500.Saigal C. S., Gore J. L., Krupski T. L. et al. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 2007;110: 1493–500.11. Harlan L. C., Potosky A., Gilliland F. D. et al. Factors associated with initial therapy for clinically localized prostate cancer: Prostate Cancer Outcome Study. J Natl Cancer Inst 2001;93:1864–71.Harlan L. C., Potosky A., Gilliland F. D. et al. Factors associated with initial therapy for clinically localized prostate cancer: Prostate Cancer Outcome Study. J Natl Cancer Inst 2001;93:1864–71.12. Graefen M., Schlomm T. Martini. Is radical prostatectomy a useful therapeutic option for high-risk prostate cancer in older men? Oncologist 2012;17 Suppl 1:4–8.1Graefen M., Schlomm T. Martini. Is radical prostatectomy a useful therapeutic option for high-risk prostate cancer in older men? Oncologist 2012;17 Suppl 1:4–8.13. Alibhai S. M., Leach M., Tomlinson G. et al. 30-day mortalityand major complications after radical prostatectomy: influence of age and comorbidity. J Natl Cancer Inst 2005;97 (20):1525–32.Alibhai S. M., Leach M., Tomlinson G. et al. 30-day mortalityand major complications after radical prostatectomy: influence of age and comorbidity. J Natl Cancer Inst 2005;97 (20):1525–32.14. Chen R. C., Clark J. A., Talcott J. A. Individualizing quality-of-life outcomes reporting: how localized prostate cancer treatments affect patients withdifferent levels of baseline urinary, bowel, and sexual function. J Clin Oncol 2009;27 (24):3916–22.Chen R. C., Clark J. A., Talcott J. A. Individualizing quality-of-life outcomes reporting: how localized prostate cancer treatments affect patients withdifferent levels of baseline urinary, bowel, and sexual function. J Clin Oncol 2009;27 (24):3916–22.15. Stanford J. L., Feng Z., Hamilton A. S. et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA. 2000;283(3):354–60.Stanford J. L., Feng Z., Hamilton A. S. et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA. 2000;283(3):354–60.16. Kundu S. D., Roehl K. A., Eggener S. E. et al. Potency, continence and complications in 3,477 consecutive radical retropubic prostat-ectomies. J Urol 2004;172 (6 Pt 1):2227– 31.Kundu S. D., Roehl K. A., Eggener S. E. et al. Potency, continence and complications in 3,477 consecutive radical retropubic prostat-ectomies. J Urol 2004;172 (6 Pt 1):2227– 31.17. Sanchez-Salas R., Prapotnich D., Rozet F. et al. Laparoscopic radical prostatectomy is feasible and effective in ‘fit’ senior men with localized prostate cancer. BJU Int 2010;106 (10):1530–6.Sanchez-Salas R., Prapotnich D., Rozet F. et al. Laparoscopic radical prostatectomy is feasible and effective in ‘fit’ senior men with localized prostate cancer. BJU Int 2010;106 (10):1530–6.18. Johansson E., Steineck G., Holmberg L. et al. Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 rando-mised trial. Lancet Oncol 2011;12 (9):891–9.Johansson E., Steineck G., Holmberg L. et al. Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 rando-mised trial. Lancet Oncol 2011;12 (9):891–9.